Bayer announces the removal of 12,000 seats after Monsanto's operation

As part of integration operations between Bayer and Monsanto, German group plans to cut 12,000
jobs (out of a total of 118,200), "a significant number of them in Germany". The company explains in a statement
in which he describes in detail the synergies expected from the $ 63 billion acquisition of Monsanto. Bayer expects an annual contribution of 2.6 billion euros since 2022 as a result of the various structural measures that will be implemented
on the ground (including, in fact, downsizing).

"The details – reads a note from the group – will be treated in the coming months". Part of the resources released should
to be used to reinforce the innovation and competitiveness of the different divisions of the group. From here 2022, the company
approximately 35 billion euros, with research and development (R & D) representing more than two billion
thirds of this figure.

The group also plans to abandon activities related to animal health, brands Consumer Health Coppertone
and Dr. Scholl's and sell its 60% stake in Currenta, a service provider to the German chemical industry.

In the Consumer, Healthcare and Pharmaceutical Divisions, Bayer announced a write-down of 3.3 billion euros for the fourth quarter,
of which 2.7 billion acquired from the Merck & Co. and Dihon divisions and 600 million from the decision not to use
a hemophilia drug factory in the German city of Wuppertal and to concentrate production in Berkeley, USA.

Managing Director Werner Baumann is under pressure to raise Bayer's stock price after falling more than
35% from the beginning of the year. Investor fears over at least 9,000 stocks also weigh on the stock
lawsuits brought against the German company for an alleged carcinogenic effect of the pesticide Monsanto Roundup.

© Reserved reproduction